SC
FBRX icon

Sepio Capital’s Forte Biosciences FBRX Stock Holding History

Sepio Capital’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-381
Closed -$326K – 363
2021
Q1 		$326K Sell
381
-1,963
-84% -$1.61M 0.03% 293
2020
Q4 		$2.13M Buy
2,344
+1,608
+218% +$1.51M 0.18% 140
2020
Q3 		$893K Buy
+736
New +$488K 0.1% 185

Other funds holding FBRX

FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Sepio Capital's FBRX Position: Q2 2021 in Review

Sepio Capital sold out of Forte Biosciences (FBRX) in Q2 2021, closing a stake of 381 shares — an estimated $326K sold.

Sepio Capital first reported a position in FBRX in Q3 2020 and held it in 3 quarters. The position peaked at $2.13M in Q4 2020. 75 funds tracked by Wall St. Rank hold FBRX as of Q2 2021.

  • Sepio Capital reported no remaining Forte Biosciences position as of Q2 2021 after selling out during the quarter.
  • Sepio Capital sold 381 Forte Biosciences shares in Q2 2021, an estimated $326K.
  • Sepio Capital first reported a position in Forte Biosciences in Q3 2020 and held it in 3 quarters.
  • Sepio Capital's Forte Biosciences position peaked at $2.13M in Q4 2020.
  • 75 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2021.

Based on Sepio Capital's 13F filing for Q2 2021, filed 26 Jul 2021.